Solana Company (HSDT)

Solana Company ( HSDT ) Q3 2025 Earnings Call November 18, 2025 4:30 PM EST Company Participants Choon Wee Chee - Executive Chairman Cosmo Jiang Dane Andreeff - President, CEO & Director Jeff Mathiesen - CFO, Treasurer & Secretary Presentation Operator Hello, and thank you for standing by. Welcome to Solana Company's Third Quarter Operating Results Conference Call.

NEWTOWN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury (“DAT”) dedicated to acquiring and holding Solana tokens (“SOL”), today announced results for the quarter ended September 30, 2025.

NEWTOWN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced that the Company will release its third quarter operating results on Tuesday, November 18, 2025, after market close.

NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ: HSDT), please note that in the first sentence of the third paragraph, the increase of the amount of "SOL" held should be roughly 0.1 million, not 1 million. The corrected release follows:

NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT or the “Company”) announced that it has entered into agreements with Helius and Twinstake (each, a “Provider,” and collectively, the “Providers”), related to non-custodial staking services. The Company is also staking its SOL holdings directly from qualified custody at Anchorage Digital Bank.

NEWTOWN, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Today, Solana Company (NASDAQ: HSDT) released the following letter from the Executive Chairman:

NEW YORK--(BUSINESS WIRE)--Solana Company (NASDAQ:HSDT) (“HSDT” or “the Company”), formerly known as Helius Medical Technologies, Inc., today announced it has selected BitGo, the digital asset infrastructure company, to serve as a custodian for the Company's holdings of SOL, the native asset of the Solana Network. The partnership supports Solana Company's digital asset treasury strategy as it continues to build its position in SOL. “Our collaboration with BitGo reinforces HSDT's commitment to a.

NEWTOWN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Solana Company, (NASDAQ:HSDT or “the Company"), formerly Helius Medical Technologies, Inc., today announced it has entered into agreements with Coinbase, BitGo and Anchorage Digital to serve as custodians as it continues amassing SOL, the native asset of the Solana Network, as part of its digital assets treasury strategy.

HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors

Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device Designation

NEWTOWN, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (the "Company" or "HSDT"), today announced its first acquisition of Solana (“SOL”) tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana Blockchain. The Company now holds over 760,190 SOL, with an average cost basis of $231. The Company also holds in excess of $335 million of cash, which it intends to use to further the digital asset treasury strategy.

Preeminent SOL-backed treasury vehicle - with potential to raise over $1.25 billion aggregate gross proceeds - unlocks capital markets to accelerate Solana's growth The financing drew participation from leading investors across traditional finance and crypto, including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic Digital NEWTOWN, Pa. , Sept. 18, 2025 /PRNewswire/ -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company") today announced that it has closed its previously announced private placement offering (the "Offering") of common stock and stapled warrants to purchase common stock (and/or pre-funded warrants to purchase shares of common stock in lieu thereof) at a purchase price of $6.881 and stapled warrants to purchase shares of common stock with an exercise price equal to $10.134 per stapled warrant.

Preeminent SOL-backed treasury vehicle - with potential to deliver over $1.25 billion - unlocks capital markets to accelerate Solana's growth The offering was led by institutional and crypto-native investors such as Pantera Capital, Summer Capital, and other prominent backers including Big Brain Holdings, Avenir, SinoHope, FalconX, Arrington Capital, Animoca Brands, Aspen Digital, Borderless, Laser Digital, HashKey Capital, and Republic Digital The SOL treasury strategy will be led by incoming Director and Executive Chairman Joseph Chee (Founder and Chairman of Summer Capital and Former Head of Investment Banking, Asia at UBS), Board Observer Cosmo Jiang (General Partner at Pantera Capital) and advisor Dan Morehead (Founder and Managing Partner of Pantera Capital) NEWTOWN, Pa. , Sept. 15, 2025 /PRNewswire/ -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company") today announced the pricing of an oversubscribed private investment in public equity offering (the "Offering") for the purchase and sale of common stock (and/or pre-funded warrants to purchase shares of common stock) at a purchase price of $6.881 and stapled warrants to purchase shares of common stock with an exercise price equal to $10.134 per stapled warrant.

NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation.

NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing on the Nasdaq Capital Market.